 |
|
Hormone drug type makes survival difference in advanced breast cancer
January 31, 2007Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.
In addition, aromatase inhibitors — drugs known as Arimidex, Aromasin and Femara — are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London.
The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women.
Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors. "Survival data was only available for about half of the women," Bliss said.
The available data showed an 11 percent reduction in the risk of death compared to women not receiving aromatase inhibitors.
The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
The treatment of advanced breast cancer in women who have gone through menopause usually involves a combination of surgery, radiation, chemotherapy, hormonal and biological therapies. In many breast cancers, estrogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman's production of estrogen.
Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so.
Other breast cancer treatments that also affect estrogen include tamoxifen and progestins. Tamoxifen is the most widely used hormonal treatment in advanced breast cancer; however, it carries a risk of blood clots and other rare but potentially serious side effects.
Bliss said that the review found very little reliable data in the trials comparing the effectiveness of the different available aromatase inhibitors. "The promotion of one individual drug over another is not evidence-based and should be avoided," the authors said.
In general, women taking aromatase inhibitors had about the same risk of experiencing hot flashes as those receiving tamoxifen. However, they reported more nausea, vomiting and diarrhea when compared to patients receiving the progestin drug megestrol acetate and to a lesser extent, when compared with patients receiving tamoxifen.
Patients taking aromatase inhibitors had a decreased risk of vaginal bleeding and blood clots compared to those using other hormonal therapies.
Safety data were difficult to analyze, Bliss said: "The picture is patchy due to poor quality of adverse event reporting and different study endpoints," in the various trials.
However, "the review findings do confirm modest, but real therapeutic benefits from the use of aromatase inhibitors in a variety of clinical settings," Bliss said.
Edith Perez, M.D., an oncologist with the Multidisciplinary Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., said, "The results of the review are not a surprise. These are good drugs and they have positively impacted the lives of patients with breast cancer." Perez is not associated with the review.
Perez believes that aromatase inhibitors are the first drug of choice for hormonal treatment of advanced breast cancer in postmenopausal women. "They have a slightly improved efficacy over tamoxifen, and they have a much lower rate of blood clots in the legs and lungs," she said. "Aromatase inhibitors carry almost no risk of uterine cancer, and while that rarely happens with tamoxifen, it does happen."
On the other hand, Perez said that aromatase inhibitors do carry a risk of increased joint aches and, more importantly, may cause bone loss. "The majority of patients do very well but we recommend patients have bone density tests before using these drugs. I would probably not use aromatase inhibitors in a patient with severe osteoporosis."
While per-tablet cost of aromatase inhibitors is higher than tamoxifen, Perez said that they are still cost-effective because they have fewer side effects requiring treatment and they result in increased overall survival.
"It's no question that these drugs are better for patients when compared with other hormone therapies," Perez said.
Center for the Advancement of Health
Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors. "Survival data was only available for about half of the women," Bliss said.
The available data showed an 11 percent reduction in the risk of death compared to women not receiving aromatase inhibitors.
The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
The treatment of advanced breast cancer in women who have gone through menopause usually involves a combination of surgery, radiation, chemotherapy, hormonal and biological therapies. In many breast cancers, estrogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman's production of estrogen.
Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so.
Other breast cancer treatments that also affect estrogen include tamoxifen and progestins. Tamoxifen is the most widely used hormonal treatment in advanced breast cancer; however, it carries a risk of blood clots and other rare but potentially serious side effects.
Bliss said that the review found very little reliable data in the trials comparing the effectiveness of the different available aromatase inhibitors. "The promotion of one individual drug over another is not evidence-based and should be avoided," the authors said.
In general, women taking aromatase inhibitors had about the same risk of experiencing hot flashes as those receiving tamoxifen. However, they reported more nausea, vomiting and diarrhea when compared to patients receiving the progestin drug megestrol acetate and to a lesser extent, when compared with patients receiving tamoxifen.
Patients taking aromatase inhibitors had a decreased risk of vaginal bleeding and blood clots compared to those using other hormonal therapies.
Safety data were difficult to analyze, Bliss said: "The picture is patchy due to poor quality of adverse event reporting and different study endpoints," in the various trials.
However, "the review findings do confirm modest, but real therapeutic benefits from the use of aromatase inhibitors in a variety of clinical settings," Bliss said.
Edith Perez, M.D., an oncologist with the Multidisciplinary Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., said, "The results of the review are not a surprise. These are good drugs and they have positively impacted the lives of patients with breast cancer." Perez is not associated with the review.
Perez believes that aromatase inhibitors are the first drug of choice for hormonal treatment of advanced breast cancer in postmenopausal women. "They have a slightly improved efficacy over tamoxifen, and they have a much lower rate of blood clots in the legs and lungs," she said. "Aromatase inhibitors carry almost no risk of uterine cancer, and while that rarely happens with tamoxifen, it does happen."
On the other hand, Perez said that aromatase inhibitors do carry a risk of increased joint aches and, more importantly, may cause bone loss. "The majority of patients do very well but we recommend patients have bone density tests before using these drugs. I would probably not use aromatase inhibitors in a patient with severe osteoporosis."
While per-tablet cost of aromatase inhibitors is higher than tamoxifen, Perez said that they are still cost-effective because they have fewer side effects requiring treatment and they result in increased overall survival.
"It's no question that these drugs are better for patients when compared with other hormone therapies," Perez said.
Center for the Advancement of Health
Aromatase Inhibitor Current Events and Aromatase Inhibitor News RSSStudy of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop.
Low-dose estrogen shown safe and effective for metastatic breast cancer
When estrogen-lowering drugs no longer control metastatic breast cancer, the opposite strategy might work. Raising estrogen levels benefited 30 percent of women whose metastatic breast cancer no longer responded to standard anti-estrogen treatment.
PET scan can non invasively measure early assessment of treatment for common type of breast cancer
Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting next week.
Mayo Clinic researchers say agent provides treatment option for women with hot flashes
A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Progress made in understanding causes and treatment of endometriosis
Endometriosis is a poorly understood chronic disease characterized by infertility and chronic pelvic pain during intercourse. It affects between 5 to 10 million women in the U.S.
Meta-analyses of global trials finds in favor of aromatase inhibitors
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
Risk assessment plays key role in long-term treatment of breast cancer
Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence.
Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer.
13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
More Aromatase Inhibitor Current Events and Aromatase Inhibitor News Articles
 |
CHRYSIN 500 - 60 Capsules 500mg Aromatase Inhibitor by Bionutricals Scientific studies show that flavones (primarily chrysin) may exert a wide variety of powerful effects. Specifically, studies done in Europe show that after supplementing with chrysin blood serum levels of testosterone went up a whopping 30%! How does this work? There are two major hormones in both men and women is: testosterone and estrogen. Testosterone is dominant in men and estrogen is dominant in women. But interestingly, estrogen seems to be a signal to the pituitary gland in the brain. Based on estrogen levels, the pituitary turns on or off testosterone production. The higher the estrogen levels, the lower the amounts of testosterone will be produced. This is where chrysin comes in! Chrysin basically reduces estrogen levels by cutting down on its conversion from testosterone |
 |
Chrysin Surge - 90 Capsules 500mg Aromatase Inhibitor Anti-Estrogen Increase Testosterone by Physiomuscle Scientific studies show that flavones (primarily chrysin) may exert a wide variety of powerful effects. Specifically, studies done in Europe show that after supplementing with chrysin blood serum levels of testosterone went up 30%! How does this work? The two major hormones in both men and women are: testosterone and estrogen. Testosterone is dominant in men and estrogen is dominant in women. But interestingly, estrogen seems to be a signal to the pituitary gland in the brain. Based on estrogen levels, the pituitary turns on or off testosterone production. The higher the estrogen levels, the lower the amounts of testosterone will be produced. This is where chrysin comes in! Chrysin basically reduces estrogen levels by cutting down on its conversion from testosterone. |
 |
SAN Estrodex Aromatase Inhibitor, Capsules , 90 capsules by San Innovations for the serious minded athlete. Estrodex is a new ground breaking formula that is designed to optimize and create an anabolic environment by decreasing estrogen and increasing testosterone levels. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. |
 |
Aromatase Inhibitors: Types, Mode of Action and Indications (Cancer Etiology, Diagnosis and Treatment Series) by Jean R. Lamonte (Editor), Masanori Shirmodaira (Editor), Tomohiro Nakayama (Editor), Helena Aguilar (Editor), Ander Urruticoechea (Editor), Mosammat Rashida Begum (Editor) Aromatase inhibitors (AI) are a class of drugs used in the treatment of breast cancer and ovarian cancer in postmenopausal women. Aromatase is an enzyme that synthesises oestrogen and aromatase inhibitors block the synthesis of oestrogen, which is needed in some cancers to grow. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumour tissue. In contrast to pre-menopausal women, in whom most of the oestrogen is produced in the ovaries, in post-menopausal women most of the body's oestrogen is produced in the adrenal gland from the conversion of androgens. Investigations are ongoing to look for other applications and researchers continue to study aromatase inhibitors as a way to stimulate ovulation or suppress oestrogen... |
 |
IBE Nutrition FORMEX Aromatase Inhibitor/Pro-Anabolic by IBE Nutrition The same company that brought you new innovations like acetylated resveratrol, 2-bromomelatonin, and Epistane IBE is proud to announce its latest innovation: Formex. The wait for the most potent anti-estrogen ever to hit the market is over. Formex is a revolution in the battle against estradiol because it utilizes one of the most potent second generation steroidal aromatase inhibitors and supercharges it by rearranging the 17B-hydroxyl group to give you the longest lasting, legal anti-estrogen. This rearrangement, called methylcyclopentyl ether (MCPE), is what allows for the incredible increase in bioavailability, allowing for a smaller dose with much greater testosterone boosting and estradiol reducing effects. Don't waste your money on regular formestane, which hastily breaks down in... |
 |
House Of Muscle EstroBlock -- Anti-Estrogen/Aromatase Inhibitor -- 60 Capsules by House Of Muscle EstroBlock helps increase the body's ability to block the harmful side effects of high estrogen levels and boosts natural testosterone production. Each bottle contains 60 capsules and each capsule contains 100mg of Calcium D-Glucarate, 100mg of Diindolymethane and 200mg of 5.7 dihydroxyflavone. |
 |
New Treatments for Breast Cancer Breast cancer is becoming a greater threat to women's health, but there are new treatments emerging that will help women with the battle, including tumor vaccines and therapies which enhance immune response to cancer. This program focuses on the newest treatments emerging from research and for which patients they will be most appropriate. Ellie Guardino, M.D., PhD., is an Instructor in the Department of Medical Oncology at Stanford University School of Medicine. Dr. Guardino earned her MD/PhD in Microbiology and Immunology from Georgetown University. Following her residency in Internal Medicine at Harvard, she completed a fellowship in the Department of Medicine, Division of Oncology, at Stanford. Dr. Guardino is developing immune therapies and vaccines for breast cancer including... |
|
Guideline: use aromatase inhibitor as adjuvant Tx.(tamoxifen): An article from: Internal Medicine News by Diana Mahoney (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on June 15, 2005. The length of the article is 1138 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Guideline: use aromatase inhibitor as adjuvant Tx.(tamoxifen) Author: Diana Mahoney Publication: Internal Medicine News (Magazine/Journal) Date: June 15, 2005 Publisher: Thomson Gale Volume: 38 Issue: 12 Page: 22(1) Distributed by Thomson... | |
 |
Hi-Tech Estrogenex, 90 Tablets by Hi-Tech Pharmaceuticals Hi-Tech Estrogenex, 90 tabs |
|
Aromatase inhibitors impressive against breast ca: adjuvant therapy.(Women's Health)(breast cancer): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2004. The length of the article is 1032 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Aromatase inhibitors impressive against breast ca: adjuvant therapy.(Women's Health)(breast cancer) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: February 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 3 Page: 62(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |